Plain-English translation of NCT07211542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing SHR-1905, a new injectable medication designed to treat moderate-to-severe atopic dermatitis—a skin condition that causes intense itching, redness, and inflammation. About 75 patients will receive either the medication at one of two doses or a placebo (a dummy injection with no active medicine) to see if the treatment works and is safe.
Many people with severe atopic dermatitis struggle to control their symptoms with existing treatments. This trial is exploring whether this medication could offer a new, effective option for patients who need better relief from their skin condition.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to receive either the medication or a placebo as an injection. You will not know which group you are in (this is called a 'blinded' study). You will need to attend regular clinic visits so the research team can monitor how your skin responds and check for any side effects. The study will track improvements in your symptoms and overall skin health over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Enrollment target
~75 participants
Started
November 2025
Primary completion
September 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ran Li
Guangdong Hengrui Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.